Search

Your search keyword '"Nguyen, Tran Nam"' showing total 2 results
Start Over Author "Nguyen, Tran Nam" Publisher centers for disease control and prevention (cdc)
2 results on '"Nguyen, Tran Nam"'

1. Emerging Coxsackievirus A6 Causing Hand, Foot and Mouth Disease, Vietnam

Author

Nguyen Thi Han Ny, Sarawathy Sabanathan, Le Nguyen Thanh Nhan, Guy E. Thwaites, Ho Lu Viet, Nguyen Thi Thu Hong, Lam Anh Nguyet, Tran Tan Thanh, Phan Tu Qui, Ha Manh Tuan, H. Rogier van Doorn, Nguyen Van Vinh Chau, Maia A. Rabaa, Vu Thi Ty Hang, Do Chau Viet, Nguyen Thanh Hung, Nguyen To Anh, Truong Huu Khanh, Louise Thwaites, Le Nguyen Truc Nhu, Bridget Wills, Hoang Minh Tu Van, Nguyen Tran Nam, Tran Thi Lan Phuong, and Le Van Tan

Subjects
Male, 0301 basic medicine, Epidemiology, Hand foot and mouth disease, lcsh:Medicine, phylogeny, Communicable Diseases, Emerging, Hand-foot-and-mouth disease, Pandemic, Child, Foot-and-mouth disease, Genomics, 3. Good health, Phylogeography, Infectious Diseases, Vietnam, Female, Adult, Microbiology (medical), medicine.medical_specialty, Asia, Adolescent, Coxsackievirus Infections, Genome, Viral, Biology, Coxsackievirus, Disease cluster, enteroviruses, lcsh:Infectious and parasitic diseases, Young Adult, deep sequencing, 03 medical and health sciences, Emerging pathogen, stomatognathic system, medicine, Humans, viruses, lcsh:RC109-216, coxsackievirus A6, Whole Genome Sequencing, Research, Public health, lcsh:R, Outbreak, medicine.disease, biology.organism_classification, Enterovirus A, Human, 030104 developmental biology, Emerging Coxsackievirus A6 Causing Hand, Foot and Mouth Disease, Vietnam, Hand, Foot and Mouth Disease, Demography
Abstract

Hand, foot and mouth disease (HFMD) is a major public health issue in Asia and has global pandemic potential. Coxsackievirus A6 (CV-A6) was detected in 514/2,230 (23%) of HFMD patients admitted to 3 major hospitals in southern Vietnam during 2011-2015. Of these patients, 93 (18%) had severe HFMD. Phylogenetic analysis of 98 genome sequences revealed they belonged to cluster A and had been circulating in Vietnam for 2 years before emergence. CV-A6 movement among localities within Vietnam occurred frequently, whereas viral movement across international borders appeared rare. Skyline plots identified fluctuations in the relative genetic diversity of CV-A6 corresponding to large CV-A6-associated HFMD outbreaks worldwide. These data show that CV-A6 is an emerging pathogen and emphasize the necessity of active surveillance and understanding the mechanisms that shape the pathogen evolution and emergence, which is essential for development and implementation of intervention strategies.

Published
2018

2. Workshop on Use of Intravenous Immunoglobulin in Hand, Foot and Mouth Disease in Southeast Asia

Author

Yibing Cheng, Tawee Chotpitayasunondh, Mong How Ooi, Marcel Wolbers, H. Rogier van Doorn, Zen Hafy, Sokkosal Chea, Mei Zeng, Surinda Kawichai, Nguyen Tran Nam, Ching Chuan Liu, and Kulkanya Chokephaibulkit

Subjects
IVIg, Microbiology (medical), medicine.medical_specialty, workshop, Epidemiology, MEDLINE, hand foot and mouth disease, lcsh:Medicine, Hand-foot-and-mouth disease, lcsh:Infectious and parasitic diseases, Southeast asia, stomatognathic system, intravenous immunoglobulin, medicine, Humans, lcsh:RC109-216, Intensive care medicine, enterovirus 71, Asia, Southeastern, Randomized Controlled Trials as Topic, Foot-and-mouth disease, enterovirus, business.industry, lcsh:R, Immunoglobulins, Intravenous, Online Report, medicine.disease, Southeast Asia, Surgery, Clinical trial, Workshop on Use of Intravenous Immunoglobulin in Hand, Foot and Mouth Disease in Southeast Asia, Infectious Diseases, Clinical research, Infectious disease (medical specialty), Inclusion and exclusion criteria, Hand, Foot and Mouth Disease, business
Abstract

A randomized, placebo-controlled clinical trial is needed to determine efficacy and safety of this treatment method., The South East Asia Infectious Disease Clinical Research Network convened subject matter experts at a workshop to make consensus recommendations for study design of a clinical trial for use of intravenous immunoglobulin (IVIg) in severe hand, foot and mouth disease (HFMD). HFMD is a highly contagious emerging infection among children in the region, a small proportion of whom develop neurologic and cardiopulmonary complications with high case-fatality rates. The use of IVIg for treatment of severe disease is widespread and a part of local, national, and international guidelines, but no clinical evidence warrants the use of this drug, which is expensive and has potentially serious side effects. During a 2-day workshop in March 2014, a group of HFMD experts reviewed the current evidence related to use of IVIg in HFMD and discussed potential study design, feasibility, inclusion and exclusion criteria, sample size, primary and secondary endpoints, and subsidiary studies for a randomized, placebo-controlled trial.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results